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Urinary tract infections (UTIs) are among the most common infectious diseases of humans, with Escherichia coli responsible for
>80% of all cases. One extreme of UTI is asymptomatic bacteriuria (ABU), which occurs as an asymptomatic carrier state that
resembles commensalism. To understand the evolution andmolecular mechanisms that underpin ABU, the genome of the ABU
E. coli strain VR50 was sequenced. Analysis of the complete genome indicated that it most resembles E. coli K-12, with the addi-
tion of a 94-kb genomic island (GI-VR50-pheV), eight prophages, andmultiple plasmids. GI-VR50-pheV has a mosaic structure
and contains genes encoding a number of UTI-associated virulence factors, namely, Afa (afimbrial adhesin), two autotransporter
proteins (Ag43 and Sat), and aerobactin. We demonstrated that the presence of this island in VR50 confers its ability to colonize
the murine bladder, as a VR50 mutant with GI-VR50-pheV deleted was attenuated in a mouse model of UTI in vivo. We estab-
lished that Afa is the island-encoded factor responsible for this phenotype using two independent deletion (Afa operon and AfaE
adhesin) mutants. E. coli VR50afa and VR50afaE displayed significantly decreased ability to adhere to human bladder epithelial
cells. In the mouse model of UTI, VR50afa and VR50afaE displayed reduced bladder colonization compared to wild-type VR50,
similar to the colonization level of the GI-VR50-pheVmutant. Our study suggests that E. coli VR50 is a commensal-like strain
that has acquired fitness factors that facilitate colonization of the human bladder.
Urinary tract infections (UTIs) are among the most commoninfectious diseases of humans and a major cause of morbid-
ity. It is estimated that 40 to 50% of all adult women experience at
least one UTI episode in their lifetime (1). In addition to well-
documented symptomatic infections, many UTIs are asymptom-
atic. These infections, referred to as asymptomatic bacteriuria
(ABU), represent a carrier state that resembles commensalism and
occur in a percentage of the population, depending on age and
gender. ABU patients may carry 105 CFU of a single bacterial
strain/ml of urine for months or years without significant symp-
toms.
Escherichia coli causes more than 80% of all symptomatic and
asymptomatic UTIs. In general, strains that cause symptomatic
UTI are collectively described as uropathogenic E. coli (UPEC),
while strains that cause asymptomatic UTI are referred to as ABU
E. coli. Both UPEC and ABU E. coli strains exhibit a high degree of
genetic diversity that is largely attributed to the presence of viru-
lence/fitness genes on mobile genetic elements referred to as
pathogenicity islands (PAIs) or genomic islands (GIs) (2, 3).
While no single virulence factor is uniquely definitive forUPECor
ABU E. coli, the ability to colonize the urinary tract is enhanced by
a number of factors, including fimbriae (e.g., type 1, P, F1C, and
Afa), autotransporter proteins (e.g., Ag43, UpaB, and UpaH), cell
surface polysaccharides (e.g., O antigen), and siderophores (e.g.,
enterobactin, salmochelin, aerobactin, and yersiniabactin) (4–8).
The clinically benign nature of ABU was initially explained by
a lack of virulence, since phenotypically, many ABU E. coli strains
lack adhesins and toxins commonly associated with virulence.
However, there are inconsistencies in these observations with re-
spect to strain genotype, and it is now apparent that many ABU E.
coli strains have arisen from virulent UPEC strains that have be-
come attenuated through gene loss or deletion (9, 10). This is
supported by the observation that ABU strains often possess vir-
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ulence genes, such as those encoding type 1 fimbriae, P fimbriae,
or hemolysin, but do not express the associated phenotype (9–12).
Molecular and genomic analyses of the ABU prototype E. coli
strain 83972 also support this observation.E. coli 83972 is a clinical
isolate capable of long-term bladder colonization, as shown in
human inoculation studies (13–15). The virulence-associated ad-
hesin genes of E. coli 83972 have become attenuated through a
series of independent mutational events. The type 1 fimbrial sys-
tem has been inactivated by amajor deletion encompassing 4.5 kb
of the fim gene cluster affecting all genes except those encoding the
minor components, namely, fimF, fimG, and fimH (16). The F1C
system has been inactivated by point mutations in the fimbrial
transport system affecting the focD gene encoding the usher pro-
tein (17). Finally, the P fimbrial system has been inactivated by
point mutations in the papG gene that have rendered the PapG
adhesin nonfunctional (16). Thus, the ancestor of E. coli 83972,
which belongs to the B2 clonal group, was most likely a virulent
UPEC strain that has become attenuated (18). Recently, E. coli
83972 adaptation to the human urinary tract has also been linked
to its ability to suppress RNA polymerase II-dependent host gene
expression following human bladder colonization, thereby pre-
venting the activation of host proinflammatory responses during
infection (19).
A second group of ABU E. coli strains comprises commensal-
like strains that have acquired fitness factors that contribute to
colonization of the bladder (10). Little is understood about the
genetic makeup of these strains or the factors that contribute to
their prolonged survival without inducing a proinflammatory
host response. In this study, we obtained a complete genome se-
quence of the ABU E. coli strain VR50. We show that E. coli VR50
ismost closely related to commensalE. coli strains, particularly the
K-12 strainMG1655, with themajor difference being the presence
of mobile genetic elements, including a large 94-kb genomic is-
land (GI-VR50-pheV), prophage regions, and plasmids. GI-
VR50-pheV has a mosaic composition of genes, and we show that
the genes encoding the Afa adhesin (which are located within GI-
VR50-pheV) contribute significantly to VR50 adherence to blad-
der epithelial cells and colonization of the mouse bladder.
MATERIALS AND METHODS
Bacterial strains and growth conditions. E. coli VR50 (serotype OR:K1:
H) was isolated from a 30-year-old otherwise healthy woman who had
carried it for at least 1 year without any symptoms (20). E. coli 83972 and
UPEC CFT073 have been described previously (21, 22). Bacteria were
routinely grown at 37°C on solid or in liquid Luria-Bertani (LB) medium
supplemented with appropriate antibiotics unless otherwise stated (23).
DNA manipulations and genetic techniques. Chromosomal DNA
was purified using the Ultraclean Microbial DNA isolation kit (Mo Bio
Laboratories). PCRwas performedusingTaqpolymerase according to the
manufacturer’s instructions (Roche, Australia). Sequencing of PCRprod-
ucts was performed by the Australian Genome Research Facility. The E.
coli VR50 phylogenetic group of origin was determined using a three-
locus PCR-based method (24).
Construction ofmutants.E. coliVR50deletionmutants (VR50pheV-GI,
VR50afa, VR50afaE, VR50fim, and VR50fimH) were constructed using
the -Red recombinase gene replacement system (25). Briefly, the kana-
mycin gene from plasmid pKD4 was amplified using primers containing
50-nucleotide (nt) homology extensions to the beginnings and ends of the
gene clusters to be deleted. The following primers were used: VR50pheV-
GI , 1772 (5 = -CTGTGCAACATACTCACCATTATGGTAAG
CGTGCAGCAAGAACCGTATTGGGCCTGGTGATGATGGCGGGA
TCG) and 1773 (5=-CCATCAGCCAGCTTATCATTCAGTAGAAGTTG
ATAAGCGGGTGTTGCCAGTCAGAAGAACTCGTCAAGAAGGCG);
VR50afa, 490 (5=-ATGAGGGAGCGATATCTGTATCTTGCTGACACC
CCTCAGGGGATACTGATGTGTAGGCTGGAGCTGCTTC) and 491
(5=-TCAATTTGTCCAGTAACCGCCAGTCAGTGTTAAAGTGTAATT
ACCAGTCGCATATGAATATCCTCCTTAG); VR50afaE, 827 (5=-AAA
AACGCAGCGCCGGTATGAATGAATTACGTCATCCGGGAAGCACA
CAGGTGTAGGCTGGAGCTGCTTC) and 828 (5=-GCTCCTTTGTTGA
TCTATTTTTTATTATCGGCCAGTGATTGATTGGTTCCCATATGAA
TATCCTCCTTAG); VR50fim, 244 (5=-GTCGATTGAGGATTTCGGAT
ATTGATCTTAAGGCAAAGTGGTGTAGGCTGGAGCTGCTTC) and
245 (5=-GCTCCTAACGATACCGTGTTATTCGCTGGAATAATCGTA
CCATATGAATATCCTCCTTAG); andVR50fimH, 787 (5=-AGTGATTA
GCATCACCTATACCTACAGCTGAACCCGAAGAGATGATTGTAGT
GTAGGCTGGAGCTGCTTC) and 788 (5=-TAGCTTCAGGTAATATTG
CGTACCAGCATTAGCAATGTCCTGTGATTTCTCATATGAATATC
CTCCTTAG). The primers were used to amplify a 1.6-kb PCR product
from plasmid pKD4, representing the kanamycin resistance cassette from
pKD4 and additional 50-bp overhang regions at the 5= and 3= ends of the
PCR product complementary to the target genes in VR50. The mutants
were constructed by transforming VR50(pKD46) with the PCR product
containing the homology arms and selection of kanamycin-resistant col-
onies. The kanamycin cassette was then removed using plasmid pCP20
(25). All deletions were confirmed by PCR and sequencing.
Agglutination assays. Afa-mediated mannose-resistant hemaggluti-
nation (MRHA) was assessed as previously described (26). Briefly, a 5%
suspension (10 l) of human type A red blood cells (RBCs) washed in
phosphate-buffered saline (PBS)wasmixedwith a 10-l bacterial suspen-
sion on glass slides in the presence and absence of D-mannose. The bac-
terial suspension was prepared by transferring cells from a freshly grown
LB agar colony into 50 l PBS.
Adhesion assays. E. coli binding to human HeLa and T24 bladder
epithelial cells was assessed by a quantitative adhesion assay using conflu-
ent monolayers of epithelial cells (12). Epithelial cells were seeded into
24-well cell culture plates (Corning Inc., NY) at a concentration of 3 105
cells per well and incubated overnight at 37°C in 5% CO2 prior to infec-
tion. Themonolayers were washed with PBS and inoculated with bacteria
at a multiplicity of infection of 50 bacteria per epithelial cell for HeLa cell
assays and 10 bacteria per epithelial cell for T24 cell assays. The bacteria
were prepared by washing an overnight culture grown in LB once in PBS
(3,500 g; 15 min; 4°C) and resuspended to a concentration of 1.5 107
CFU/ml in RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 2 mM glutamine (HeLa cell assays) or McCoy’s
5A modified medium (Life Technologies) supplemented with 10% heat-
inactivated FBS (T24 cell assays). The infectedmonolayerswere incubated
at 37°C for 2 h (HeLa cells) or 1 h (T24 cells) in 5% CO2 and then washed
four times with PBS to remove nonadherent bacteria. The monolayers
(n  4) were lysed with 0.01% Triton X-100 in distilled water, and the
lysates were diluted in PBS to obtain quantitative colony counts of bacte-
ria on agar. Data pooled from a minimum of three independent experi-
ments are presented as the mean number of CFU/ml plus the standard
error of the mean (SEM).
Genome sequencing and assembly. The genome sequence of E. coli
VR50 was determined using a combination of 454 (Roche) pyrosequenc-
ing (24 coverage) and traditional Sanger sequencing (1 coverage)
(Australian Genome Research Facility). The following reads were in-
cluded in the final assembly. (i) 1.2 million 454 GS20 shotgun reads (av-
erage read length, 101 bp); (ii) 85,155 454 GS-FLX 20-bp mate pair reads
(average distance between reads, 2 kb); (iii) 7,680 Sanger mate pair reads
from a pUC clone library with an insert size range of 5 to 8 kb; and (iv) 384
Sanger end sequences from 192 gap-spanning PCR products. A hybrid
assembly of 25 scaffolds (230 contigs) using GS-20, GS-FLX, and Sanger
reads was produced using the GS De Novo Assembler (version 1.1.02.15)
(Roche). The physical map of the chromosome was also determined by
OpGen Technologies, Inc. (Madison, WI), using the restriction enzyme
NcoI and the optical-mapping technique. The order and orientations of
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the scaffolds were confirmed by aligning the scaffolds on the optical map
using Opgen Mapviewer. Gaps between linked contigs were closed either
by walking on gap-spanning clones or with PCR products generated from
genomic DNA. While the chromosome was finished to high quality, all
attempts to unambiguously resolve the plasmid-related contigs were un-
successful due to their highly repetitive nature. Therefore, two PacBio
single-molecule real-time (SMRT) cells were carried out using the Pacific
Biosciences RSII platform to close the plasmids and complete the genome.
PacBio sequencing was carried out by shearing two aliquots of4 g
genomic E. coli VR50 DNA, using g-Tube (Covaris), into fragments size
targeted at 10 kb. The sheared samples were then purified and concen-
trated using washed Agencourt AMPure XP magnetic beads (Beckman
Coulter Inc.) with size selection at 0.45-fold volume. Subsequently,
SMRTbell template libraries were prepared using the commercial tem-
plate preparation kit from Pacific Biosciences Inc. In brief, the DNA was
end repaired, and adapters were ligated, followed by exonuclease diges-
tion of incompletely ligated products. Using the provided P4-C2 DNA/
polymerase binding kit from Pacific Biosciences, 0.83 nM libraries was
then annealed with sequencing primers and bound to 50 nM P4 DNA
polymerase. For enhanced loading efficiency into the sequencing zero-
mode waveguides (ZMWs), 15 pM bound complexes was immobilized
into Magbeads (Pacific Biosciences Inc.) according to the accompanying
protocols. During sequencing, the duration of the sequence collectionwas
set at 120 min with the stage start option. Upon acquisition of the se-
quencing data, short reads that were less than 50 bp were filtered off, and
the minimum polymerase read quality was set at 0.75.
De novo genome assemblies of PacBio sequence reads were produced
using SMRTPortal (v2.0.0) and the hierarchical genome assembly process
(HGAP) (27), with default settings and a seed read cutoff length of 5,000
bp to ensure accurate assembly across E. coli rRNA operons. The hybrid
454/Sanger and PacBio assemblies were compared usingMUMmer3 (28),
Artemis Comparison Tool (29), andmauve (30), and discrepancies between
the assemblies were investigated at the read level using BAMview (31).
Detection of DNAmodifications was carried out using the RS_Modi-
fication_and_Motif_Analysis.1 tool from the SMRT analysis package ver-
sion 2.2.0. In brief, PacBio reads were mapped to the complete VR50
genome. The polymerase kinetics, interpulse durations (IPDs) (32), were
measured for each base, andmethylated bases were identified by compar-
ison of IPD ratios against an in silico kinetic reference model (details are
available from Pacific Biosciences) and against the expected IPD signa-
tures of the three bacterial methylation types: m6A, m4C, and m5C (33).
Sequencemotifs were identified using PacBioMotif finder v1 with a qual-
ity value (QV) cutoff of 30.
Genome annotation and comparative analysis. Annotation of the
VR50 genome was performed by transferring the high-quality annotation
of E. coli K-12 MG1655, used as a main reference, and E. coli EDL933,
UTI89, CFT073, and 536 when relevant, using the Rapid Annotation
Transfer Tool (RATT) (34). Complementary annotation data were pro-
vided by the Rapid Annotations Using Subsystems Technology (RAST)
server (35).Manual curationwas also performed to ensure the accuracy of
the annotations transferred, with particular attention to regions of differ-
ences, prophage-related regions, and pseudogenes. BRIG (36), Artemis
Comparison Tool (29), andmauve (30) were used to visually compare the
VR50 assembly with various other genomes in order to identify regions of
similarity and difference. High-quality single-nucleotide polymorphisms
(SNPs) (bounded by 20 exact base pair matches on both sides) in pairwise
genome comparisons were calculated using MUMmer3 (28).
An in silico multilocus sequence type (MLST) comparison of seven
housekeeping genes from E. coli VR50 and representative complete E. coli
genomes (Table 1) was carried out by retrieving the sequence fragments
for adk, fumC, gyrB, icd, mdh, purA, and recA (http://mlst.warwick.ac.uk
/mlst/). To more accurately determine the phylogenetic relatedness of E.
coli VR50 to other E. coli strains, a SNP-based tree was constructed. In
silico-simulated reads for five fully sequenced group A strains (HS,
BW2952, DH10, W3110, and MG1655) and 12 additional E. coli strains
(IAI1, EDL933, Sakai, UMN026, IAI39, SE15, S88, APEC O1, UTI89,
ED1a, CFT073, and S38) were mapped against the complete genome of
VR50 using SHRIMP 2.0 (37). Simulated 150-bp paired reads with an
insert length of 250 bpwere generated at 150-fold coverage using a custom
program (available on request). SNP calling and indel prediction were
performed using the Nesoni package (Victorian Bioinformatics Consor-
tium), and all conserved polymorphic positions in the data set were iden-
tified using the Nesoni n-way pairwise comparative-analysis tool.
Polymorphic substitution sites were extracted and concatenated, and
the resulting alignment was used for phylogenetic-tree construction.
An unrooted maximum-likelihood (ML) phylogenetic tree based on
the SNP alignment was constructed with RAxML 7.2.8 (38) using the
GTR substitution model and 1,000 bootstrap replicates. The tree was
plotted using FigTree 1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/).
Quantification of secreted IL-6. The level of interleukin 6 (IL-6) se-
creted by HeLa epithelial cells was quantified by enzyme-linked immu-
nosorbent assay (ELISA) as described by the manufacturer (R&D Sys-
tems). Culture supernatants from E. coli-stimulated epithelial cells were
collected 2 h following infection.
Mousemodel of UTI. Themousemodel of UTI was used as described
previously (39). Female C57BL/6mice (8 to 10weeks old) were purchased
from the Animal Resources Center, Western Australia, and housed in
sterile cages with ad libitum access to sterile water. An inoculum of 25 l,
containing 5 108 CFU of bacteria in PBS, was instilled directly into the
bladder using a 1-ml tuberculin syringe attached to the catheter. Urine
was collected from each mouse 18 h after inoculation for quantitative
colony counts. Groups of mice were euthanized by cervical dislocation 18
h after challenge; the bladders were then excised aseptically, weighed, and
homogenized in PBS. The bladder homogenates were serially diluted in
PBS and plated onto LB agar for colony counts. Data are expressed as the
total number of CFU per gram of bladder tissue for each mouse. Experi-
ments were performed with a minimum group size of eight.
Nucleotide sequence accession numbers. The complete chromosome
(GenBank accession no. CP011134) and plasmid (GenBank accession no.
CP011135 to CP011143) sequences have been deposited at DDBJ/EMBL/
GenBank (Bioproject PRJEA61445). The version described in this paper is
version 1.
RESULTS
Phenotypic characteristics of E. coliVR50. E. coli VR50 (OR:K1:
H) is an ABU isolate that belongs to phylogroup A. The strain
was isolated from a 30-year-old otherwise healthy woman who
had carried it for at least 1 year without any adverse effects. E. coli
VR50 causes mannose-sensitive (MS) agglutination of yeast cells
(indicative of type 1 fimbria expression) and mannose-resistant
(MR) hemagglutination of human type A red blood cells (20). E.
coli VR50 is also nonmotile and adheres strongly to HeLa epithe-
lial cells, with the level of adhesion equal to that of the well-char-
acterized pyelonephritis strain CFT073 and significantly greater
than that of the ABU strain E. coli 83972 (Fig. 1A). Since E. coli
VR50 is an ABU strain that was responsible for a prolonged infec-
tion in the absence of symptoms,we hypothesized that itmight fail
to trigger a strong proinflammatory response in comparison to
other virulentUPEC strains. To test this, we compared the abilities
of E. coli VR50 and CFT073 to stimulate IL-6 production follow-
ing adhesion to epithelial cells. The level of secreted IL-6, which is
an important proinflammatory cytokine associated with UTI, was
quantified by ELISA. Despite equivalent adherence, the level of
IL-6 secreted following adhesion of E. coli VR50 was significantly
lower than the level of IL-6 secreted following adhesion of CFT073
(P 	 0.001) (Fig. 1B). Taken together, these characteristics
prompted us to perform an in-depth analysis of E. coli VR50, as
described below.
Molecular Analysis of the ABU E. coli Strain VR50
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Genome features of E. coli VR50. The complete genome of E.
coli VR50 was determined and includes a 5,000,366-bp circular
chromosomal sequence and 9 plasmid sequences. TheVR50 chro-
mosome consists of 4,711 annotated protein-coding regions, in-
cluding 125 predicted pseudogenes, 22 rRNAs, and 85 tRNAs,
with a G
C content of 50.78%. In addition to the chromosome,
we also identified several plasmid-associated sequences. Besides 7
small plasmids, with sizes ranging from1.7 kb up to7 kb, we
identified two large plasmids, pVR50A and pVR50B, with esti-
mated sizes of 70.5 kb and 97.9 kb, respectively. The detailed re-
sults of genome analysis of VR50 and 40 other sequenced E. coli
strains can be found in Table 1.
In addition to determining the VR50 genome sequence, we
took advantage of PacBio SMRT sequencing to detect DNA base
modifications and to produce a genome-widemethylation profile.
The genomeofVR50had adeninemethylated exclusively, with the
majority (96.3%) of m6A modifications occurring at 5=-Gm6AT
C-3=deoxyadenosinemethylase (Dam)motifs (Table 2). A total of
39,361 (98%) of 40,144 Dam sites contained m6A modifications.
This frequency of Dam methylation in VR50 is consistent with
previously characterized E. coli methylomes (40–42). In addition
to Dam, VR50 encodes a single active type I restriction-modifica-
tion (R-M) system in a typical type I operon (hsdR-hsdM-hsdS)
(Table 2). The coding sequences in the operon share 100% amino
acid sequence identity with the previously characterized type I
R-M system EcoB from E. coli B; this methylase is predicted to
recognize the motif 5=-TGm6AN8TGCT-3= (methylated base on
opposite strand underlined) (Table 2). It should be noted that no
ten-eleven translocation (TET)-converted sample DNA was se-
quenced, and thus, m5C methylated bases could not be discrimi-
nated from unmodified bases.
TABLE 1 Summary of genome features of publicly available E. coli strains used in this study
Organism Pathotypea (host)
Size of
chromosome
(bp)b
GC
content
(%)b
No. of
genesb
No. of
pseudogenesb
No. of
rRNAsb
No. of
tRNAsb
No. of
prophage
regionsb
No. of
plasmidsb
GenBank
accession
no.
E. coli OR:K1:H strain VR50 ABU (human) 5,000,386 50.8 4,711 125 22 85 8 9 CP011134
E. coli O18:K1:H7 strain UTI89 UPEC (human) 5,065,741 50.6 5,066 NAc 22 88 NA 1 CP000243.1
E. coli O6:K15:H31 strain 536 UPEC (human) 4,938,920 50.5 4,685 NA 22 81 1 0 CP000247.1
E. coli OR:K5:H strain ABU 83972 ABU (human) 5,131,397 50.6 4,793 NA 22 88 6 1 CP001671
E. coli O6:H1:K2 strain CFT073 UPEC (human) 5,231,428 50.5 5,379 94 21 89 5 0 AE014075.1
E. coli O7:K1 strain IAI39 UPEC (human) 5,132,068 50.6 5,132 80 22 88 NA 0 CU928164.2
E. coli O17:K52:H18 strain UMN026 UPEC (human) 5,202,090 50.7 4,918 45 22 88 NA 2 CU928163.2
E. coli O25b:H4-ST131 strain EC958 UPEC (human) 5,109,767 50.7 4,981 25 22 89 7 2 HG941718.1
E. coli O18:K1:H7 strain IHE3034 NMEC (human) 5,108,383 50.7 4,757 NA 21 97 NA 0 CP001969
E. coli O45:K1 strain S88 NMEC (human) 5,032,268 50.7 5,049 90 22 91 NA 1 CU928161.2
E. coli OR:H48 strain K-12 substrain
W3110
K-12 (human) 4,646,332 50.8 4,227 NA 22 86 NA 0 AP009048.1
E. coli OR:H48 strain K-12 substrain
MG1655
K-12 (human) 4,639,675 50.8 4,294 81 22 89 10 0 U00096.2
E. coli OR:H48 strain K-12 substrain
DH10B
K-12 (human) 4,686,137 50.8 4,200 NA 22 86 10 0 CP000948.1
E. coli OR:H48 strain K-12 substrain
BW2952
K-12 (human) 4,578,159 50.8 4,098 NA 22 88 NA 0 CP001396.1
E. coli BL21(DE3) Commensal (human) 4,570,938 50.8 4,336 70 22 85 NA 0 CP001509
E. coli B strain REL606 Commensal (human) 4,629,812 50.8 4,383 67 22 85 10 2 CP000819.1
E. coli O152:H28 strain SE11 Commensal (human) 4,887,515 50.7 4,679 NA 22 86 7 6 AP009240.1
E. coli O8 strain IAI1 Commensal (human) 4,700,560 50.8 4,491 51 22 86 NA 0 CU928160.2
E. coli O9:H4 strain HS Commensal (human) 4,643,538 50.8 4,478 94 22 88 NA 0 CP000802.1
E. coli O81 strain ED1a Commensal (human) 5,209,548 50.7 4,915 95 22 91 NA 1 CU928162.2
E. coli O150:H5 strain SE15 Commensal (human) 4,717,338 50.7 4,338 NA 22 84 2 1 AP009378
E. coli W W (human) 4,900,968 50.8 4,764 91 22 87 7 2 CP002185
E. coli ATCC 8739 C (human) 4,746,218 50.9 4,409 82 22 87 8 0 CP000946.1
E. coli O19:H34 strain SMS-3-5 Environmental 5,068,389 50.5 4,743 78 22 90 4 4 CP000970.1
E. coli O178:H11 strain H10407 ETEC (human) 5,153,435 51.2 4,746 NA 22 87 9 4 FN649414
E. coli O139:H28 strain E24377A ETEC (human) 4,979,619 50.6 4,873 118 21 91 NA 6 CP000800.1
E. coli O55:H7 strain CB9615 EPEC (human) 5,386,352 50.5 5,028 69 22 101 19 1 CP001846.1
E. coli O127:H6 strain E2348/69 EPEC (human) 4,965,553 50.8 4,703 145 22 92 13 2 FM180568.1
E. coli O157:H7 strain EC4115 EHEC (human) 5,572,075 50.4 5,315 NA 22 110 NA 2 CP001164.1
E. coli O157:H7 strain TW14359 EHEC (human) 5,528,136 50.5 5,263 NA 22 106 NA 1 CP001368.1
E. coli O157:H7 strain Sakai EHEC (human) 5,498,450 50.5 5,361 247 22 105 18 1 BA000007.2
E. coli O157:H7 strain EDL933 EHEC (human) 5,528,445 50.4 5,349 NA 22 98 24 2 AE005174.2
E. coli O103:H2 strain 12009 EHEC (human) 5,449,314 50.6 5,054 209 22 98 15 1 AP010958.1
E. coli O26:H11 strain 11368 EHEC (human) 5,697,240 50.6 5,364 254 22 101 21 4 AP010953.1
E. coli O111:H strain 11128 EHEC (human) 5,371,077 50.4 4,972 291 22 106 17 5 AP010960.1
E. coli O44:H18 strain 042 EAEC (human) 5,241,977 50.5 4,810 110 22 93 9 1 FN554766
E. coli 55989 EAEC (human) 5,154,862 50.7 4,969 79 22 94 NA 1 CU928145.2
E. coli O1:K1:H7 strain APECO1 APEC (chicken) 5,082,025 50.6 4,467 NA 22 93 10 4 CP000468.1
E. coli UM146 AIEC (human) 4,993,013 50.6 4,650 NA 22 86 NA 1 CP002167
E. coli O83:H1 strain NRG 857C AIEC (human) 4,747,819 50.7 4,431 NA 22 84 5 1 CP001855
E. coli O83:H1 strain LF82 AIEC (human) 4,773,108 49.9 4,376 NA 22 84 4 1 CU651637
a AIEC, adherent-invasive E. coli; APEC, avian pathogenic E. coli; EAEC, enteroaggregative E. coli; EHEC, enterohemorrhagic E. coli; EPEC, enteropathogenic E. coli; ETEC,
enterotoxigenic E. coli; NMEC, neonatal meningitis E. coli; UPEC, uropathogenic E. coli.
b Values are given according to information retrieved from the sequence annotation combined with data from the literature, when available.
c NA, not available.
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The E. coli VR50 genome is most similar to that of the K-12
strain MG1655. To further investigate the phylogenetic relation-
ship of E. coli VR50 to other sequenced E. coli strains, an in silico
MLST comparison was carried out. VR50 was found to belong to
the sequence type (ST) 10 complex and was indistinguishable
from the K-12 strains MG1655 and W3110. Additional house-
keeping genes (i.e., arcA, aroA,mtlD, pgi, and rpoS) and the fimH
adhesin gene (43) were also found to be identical between the
K-12 and VR50 genomes. Whole-genome nucleotide compari-
sons confirmed that VR50 belongs to phylogroup A and is most
closely related to K-12 strains (Fig. 2). Pairwise comparisons be-
tween complete genomes of phylogroup A E. coli strains indicated
that the genomes of VR50 and K-12MG1655 differ by 3,953 high-
quality SNPs, with both strains differing from E. coliHS, the most
divergent phylogroup A strain, by approximately 14,500 SNPs
(Fig. 2). Although the genomes of VR50 and K-12 MG1655 are
largely syntenic, VR50 exhibits two large inversions (12.4 kb and
54.2 kb) flanked by IS629 elements. The IS629 element has ex-
panded to 19 chromosomal copies after acquisition byVR50, con-
tributing to the larger number of pseudogenes observed in the
genome (Table 1).
E. coli VR50 has acquired multiple mobile genetic elements.
To identify genomic regions thatmay be associatedwith the ability
to persist in the urinary tract, we compared the VR50 chromo-
some to other representative complete E. coli genomes using
BLAST. We defined 15 regions of differences (RDs) (Table 3) and
8 prophages (Table 4) that were differentially distributed among
39 complete representative E. coli genomes (Fig. 3). RD-8 is the
largest of these regions and carries a 94-kb phe tRNA-associated
integrative island that we refer to as GI-VR50-pheV. VR50 also
carries a 32-kb asn tRNA-associated island (RD-3) that shares
99% identitywith the high-pathogenicity island fromYersinia pes-
tis (44).While RD-3 is present in all UPEC strains and absent from
most K-12 derivative strains and commensals, it is found in the
laboratory strain BL21(DE3) and the B strain REL606.
Most of the prophage-related regions identified in the VR50
genome (VR50p1 toVR50p8) (Table 4) were not found inK-12 or
other commensal strains. Of these, 3 are lambdoid prophages
(VR50p2, VR50p4, andVR50p6) and have similarity to each other
and to the lambdoid prophages in other E. coli genomes, with the
exception of most K-12 derivative strains, from which they are
absent. Of note, VR50p6 is inserted in the mrlA gene, which en-
codes a regulator required for curli production and extracellular
matrix formation (45). VR50p3 is a P22-like phage, sharing sim-
ilarities with the only P22-like phage found in UTI89, whereas
prophages VR50p1 and VR50p8 are similar to the satellite phage
P4 (Fig. 3). VR50p7 is related to the serotype-converting Salmo-
nella phage epsilon 15 and to Eco39I-1 in UPEC strain IAI39 but
does not carry any of the genes involved in serotype conversion.
The plasmid pVR50A is an F-like conjugative plasmid, sharing
nearly 90% of its backbone with pUTI89, with a nucleotide simi-
larity of 99%. A significant portion of pUTI89 is missing in
pVR50A and is replaced by a multidrug resistance cluster that
includes several antibiotic resistance genes, including strAB
(which confers resistance to streptomycin) and folP (which con-
fers resistance to sulfonamide). Of note, a copy of the blaTEM-1
FIG 1 (A) Adhesion of E. coli VR50 and 83972 (ABU strains) and CFT073 (UPEC strain) to HeLa human epithelial cells. Epithelial cells were inoculated with
bacteria and incubated for 1 h, with adherent bacteria enumerated by direct plating and colony counts. The results are the averages of two independent
experiments plus standard errors of the mean. E. coliVR50 adhered to the cells in equal numbers to the UPEC strain CFT073. (B) ELISA demonstrating levels of
IL-6 secreted by HeLa epithelial cells infected with E. coli VR50 and CFT073. The results are the averages of four replicates plus standard errors of the mean. E.
coli VR50 stimulated a significantly reduced IL-6 response compared to CFT073, despite a similar level of adherence (P	 0.001).
TABLE 2 Active methyltransferase enzymes identified in VR50
Locus tag Coordinates Type R-M/orphan
Target
sequencea
No. in
genome
No.
detectedb
%
Methylatedb Comments
ECVR50_3796 3831641–3832477 II Orphan Gm6ATC 40,144 39,361 98 100% amino acid sequence identity
to M.EcoKDam from E .coli K-
12 MG1655
ECVR50_4827 to
ECVR50_4829
4942889–4946401 II R-M TGm6AN8TGCT 775 755 (751) 97.4 (96.9) 100% amino acid sequence identity
to M.EcoBI and S.EcoBI from E.
coli B
a Underlined nucleotides reflect methylated bases on opposite DNA strand.
b Figures for the complementary strand are in parentheses and suggest hemimethylation at 4 of 755 TGm6AN8TGCT sites.
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gene, associatedwith ampicillin resistance, was also identified, but
a truncation of its N terminus suggests its inactivation, as con-
firmed by antibiotic sensitivity phenotypic tests (data not shown).
The other large plasmid found inVR50, pVR50B, possesses a com-
plexmosaic structure comprisingmultiple insertion sequence (IS)
elements, with regions of similarity to numerousUPEC-, neonatal
meningitis E. coli (NMEC)-, and commensal-associated plasmids,
including pCE10A (strain CE10; NMEC), pECOED (strain ED1a;
commensal), pSE11-2 (SE11; commensal), and pUTI89 (UTI89;
UPEC). Plasmid pVR50B carries a tra region that is almost iden-
tical to the corresponding region in pVR50A; the sequences of
these two plasmids could only be properly resolved using PacBio
sequencing. While pVR50B does not contain any antibiotic resis-
tance genes, several putative virulence-associated cargo genes
were identified, including senB (which encodes a putative entero-
toxin), imm (which encodes a colicin Ib immunity protein), and
the toxin-antitoxin phd-doc genes. Of note, VR50 also harbors
several small plasmids that are very similar to cryptic plasmids
often associated with other commensal strains; for example,
pVR50C and pVR50D are similar to pColE1-like plasmids, and
pVR50F is similar to pSE11-6.
Taken together, our data suggest E. coli VR50 is a commensal
strain, remarkably similar to E. coli K-12, which has gained the
ability to persist in the urinary tract through gene acquisition. This
is in stark contrast to the prototypical ABU E. coli strain 83972,
which appears to have evolved through mutation and gene loss
from a virulent UPEC strain (9, 10, 15–17, 46).
The pheV genomic island in E. coliVR50 includes uropatho-
genicity genes.Themost notable chromosomal variation between
E. coli VR50 and MG1655 is a contiguous gene cluster in VR50
comprising the 94-kb genomic island GI-VR50-pheV (RD-8), a
kps capsular biosynthesis gene cluster, and a gsp type II secretion
system gene cluster (RD-9). GI-VR50-pheV is located between the
pheV tRNA gene and the ksp gene cluster (Fig. 4). It is delimited by
direct repeats (DR) that encompass the last 19 bp of the pheV
tRNA gene and a truncated tRNA gene (phe=V), equivalent to attL
and attR, left and right junction sites generated by phage insertion
(47). Consistent with the features of many other integrative is-
lands, a P4-like integrase gene is located immediately adjacent to
the 5= end of GI-VR50-pheV. The GC content of GI-VR50-pheV is
48.11% compared with the E. coli VR50 genomic average of
50.78%. GI-VR50-pheV contains several genes associated with
UPEC virulence, including (i) remnants of the pap cluster; (ii) the
iuc aerobactin biosynthesis locus and the iha siderophore recep-
tor; (iii) two autotransporter (AT)-encoding genes, flu (encoding
antigen 43 [Ag43]) and sat (encoding a secreted AT toxin); and
(iv) the afaABCDE genes, the Afa/Dr adhesin family chaperone-
usher fimbrial genes.
The gene content of GI-VR50-pheV is most similar to those of
pheV-associated genomic islands in the probiotic strain Nissle
1917, as well as UPEC strains CFT073, UMN026, 536, and IAI39
(Table 5 and Fig. 5). Like other pheV islands, GI-VR50-pheV has a
mosaic structure of defined sequence modules separated by a va-
riety of insertion sequences (Fig. 5). Modules encoding virulence
factors are highly conserved at the nucleotide level (i.e., typically
95% nucleotide identity), although not necessarily in the same
order or orientation or at the same level of completeness. Inter-
vening regions typically contain strain-specific sequences or inser-
tion sequence elements that presumably facilitate the many rear-
rangements observed between islands. For example, the 28,718-nt
region containing the sat, iuc, and iha modules in VR50 is 99%
identical to equivalent modules in the Nissle 1917, CFT073, and
FIG 2 Whole-genome nucleotide comparison of VR50 with selected sequenced E. coli genomes. Shown is a maximum-likelihood phylogenetic comparison of
VR50 with 5 phylogroup A and 14 other representative E. coli strains. Phylogenetic relationships were inferred from 212,716 polymorphic SNPs and 1,000
bootstrap replicates. Major E. coli phylogroups are labeled. Nodes are colored according to bootstrap support: 1,000 (blue), 960 (dark red), and 630 (light red).
The scale bar corresponds to the mean number of nucleotide substitutions per site.
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UMN026 pheV islands; however, sat and iuc are inverted in Nissle
1917 and iha is inverted in VR50 (Fig. 5) (48). Although in Nissle
1917 this region is also flanked by IS2-like sequences, the in-
sertion sequences found between these modules are different in
all four strains, reflecting the dynamic evolution of genomic
islands (Fig. 5).
The archetypal pheV island is from CFT073 (PAI-ICFT073).
PAI-ICFT073 contains the sat, iha, iut, and flu gene modules with a
high degree of identity to islands from Nissle 1917 and VR50; in
addition, it includes the pap operon and a hylCABD operon.
The mosaic structure of the pheV island is further illustrated by
the fact that, although it is not present in the well-characterized
UPEC strain UTI89, several modules similar to those on GI-
VR50-pheV are found on other UTI89 islands (e.g., leuX). Al-
though the K-12 and HS commensal strains do not carry a pheV
island, it is found in the sequenced ED1a commensal strain
(49). GI-ED1a-pheV contains fragments of modules typically
associated with UPEC (i.e., iha and sat), with full-length iha
and iuc loci on the nearby pheU island. The genomes of the
Shiga toxin-producing E. coli (STEC) strains Sakai, EDL933, and
TABLE 3 Major regions of differences identified in VR50 compared to other E. coli strains
Identifier
Start
nucleotide
End
nucleotide Size (bp)
Insertion
site
Virulence-related or other notable
gene(s) Description
RD-1 244012 277704 33,692 aspV tRNA yafT Lipoprotein
RD-2 1527896 1547892 19,996 ydbL_ynbG feaRB, paaABCDEFGHIJKXY Phenylacetic acid degradation
RD-3 2125253 2160033 34,780 asnT tRNA Yersiniabactin-biosynthetic cluster 99% similar to high-pathogenicity island
(HPI) from Yersinia pestis
RD-4 2172863 2192851 19,988 yeeHa flu1 Antigen 43 phase-variable biofilm
formation autotransporter
RD-5 2216480 2225524 9,044 gnd_galF O-antigen region
RD-6 3037592 3047232 9,640 iap_cysH CRISPR locus CRISPR 2.1
RD-7 3157781 3169951 12,170 glyU tRNA ETT2 cluster remnant T3SSb-related genes; similar to ETT2
sepsis (eprKa, epaS1a, eivJ2a, and
eivICAEGF missing)
RD-8 3295104 3407870 112,766 pheV tRNA pap cluster remnant; iuc, iha, flu2,
sat, and afaABCDE kps cluster
GI-VR50 pheV capsular biosynthesis
gene cluster
RD-9 3407872 3442920 35,048 kpsM_yghG gsp1 glcABGFEDC T2SSc-related genes (general secretory
pathway); glycolate metabolism genes
RD-10 3770072 3782784 12,712 rpsJ_bfr gsp2 cryptic cluster T2SS-related genes (general secretory
pathway; cryptic)
RD-11 3952087 3965106 13,019 yhiM_yhiN Tn7-related genes
RD-12 4403223 4419794 16,571 typA_dtd yihLMN, ompL, and
yihOPQRSTUVWXY
Sugar catabolism
RD-13 4704726 4718639 13,913 pheU tRNA fecIRABCDE regulon Iron dicitrate transport
RD-14 4859525 4874849 15,324 leuX tRNA Putative oxidoreductase putative
transporters
RD-15 4912259 4947503 35,244 nanS_yjiA hsdRMS, mrr, and mcrBC
sgcXBCQAER
Restriction-modification enzymes
pentose and pentitol sugar breakdown
a Pseudogene.
b T3SS, type III secretion system.
c T2SS, type II secretion system.
TABLE 4 Prophage-related regions identified in VR50
Identifier
Start
nucleotide
End
nucleotide Size (bp) Insertion site
Direct repeat
(bp) Type Virulence-related or other notable gene(s)
VR50p1 300479 312346 11,868 thrW tRNA 16 P4-like
VR50p2 800678 832594 31,917 ybhJb_ybhB NDc Lambdoid, remnant Outer-membrane porin proteins; Lom-like
outer membrane proteins
VR50p3a 1082316 1125788 43,473 torS_torT ND P22-like
VR50p4a 1369562 1420434 50,873 ompW 39 Lambdoid Lom-like outer membrane proteins
VR50p5 1678552 1691947 13,396 yneLb_hipAb ND Untypeable; remnant
VR50p6a 2324694 2371668 46,705 mrlAb 18 Lambdoid Putative DinI-like damage-inducible
proteins; outer-membrane porin
proteins; Lom-like outer-membrane
proteins
VR50p7a 2770918 2811852 40,935 yfgI_guaA ND Epsilon-like DNA adenine methylase
VR50p8 4163270 4174321 11,052 selC tRNA ND P4-like
a Prophage genomes appear to have all the genes necessary to produce fully functional phages.
b Pseudogene.
c ND, not determined.
Molecular Analysis of the ABU E. coli Strain VR50
May 2015 Volume 83 Number 5 iai.asm.org 1755Infection and Immunity
EC4115 carry a large deletion encompassing pheV and the adja-
cent kps capsular and gsp type II secretion loci. However, the pheV
tRNA gene is included in a nonsyntenic locus and is known to be
a hot spot for insertion of the locus for enterocyte effacement
(LEE) (50, 51). The afa-8 locus on a pheV genomic island has been
described previously (52), although the associated int gene is like
intP4-2, not intP4-1, and the VR50 afa locus is quite divergent
from afa-8 (see below).
GI-VR50-pheV is formed from two independent integration
events. GI-VR50-pheV is a composite structure with evidence of
two independent pheV island insertions mediated by different
IntP4-like integrase genes (Fig. 5). As observed in the well-char-
acterizedGI-536-pheV pathogenicity island (PAIV536), GI-VR50-
pheV is bound by direct repeats corresponding to the 3= end of the
pheV tRNA gene (Table 6). Like pheV islands in CFT073, Nissle
1917, and UMN026, the right-hand direct repeat (phe=V) is 19 nt
FIG 3 BRIG visualization of the E. coliVR50 genome compared with selected complete E. coli genomes colored according to the strain group or pathotype. The
innermost circles represent the GC content (black) and GC skew (purple/green) of the E. coli VR50 chromosome. BRIG shows the results of unfiltered BLASTn
searches of E. coli strains against VR50, arranged from inner to outer colored circles as follows: UPEC strains UTI89, 536, ABU83972, CFT073, IAI39, and
UMN026 (yellow); NMEC strains IHE3034 and S88 (green); K-12 derivative strains W3110, MG1655, and DH10B (orange); commensal strains BL21(DE3),
REL606, SE11, IAI1, HS, ED1a, and SE15 (red); cloneW and ATCC 8739 (clone C) strains (maroon); strain SMS-3-5 (purple); ETEC (light blue); EPEC (aqua);
enterohemorrhagic E. coli (EHEC) (blue); EAEC (dark blue); APEC (navy); and adherent-invasive E. coli (AIEC) (gray). The color intensity is proportional to the
BLASTn identity, with dark regions having high nucleotide identity and light regions having little or no nucleotide identity. E. coli VR50 genomic features are
annotated around the outermost circle: prophage regions, VR50p1 to -8, in black and regions of differences, RD-1 to -15 in green, with RD-8 depicted in brown
to allow differentiation from the contiguous RD-9.
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and contains a substitution (Table 6). Strains 536 and APECO1
share a different phe=V sequence, corresponding to a duplication
of the 23 nt at the 3= end of pheV and a single-nucleotide deletion
(Table 6) (4, 53), whereas, GI-SMS-3-5-pheV is bounded by a set
of perfect 19-nt direct repeats. Intriguingly, withinGI-VR50-pheV
there is a perfect 19-nt direct repeat of the pheV 3= region (phe=V
-2) immediately upstream of a different P4-like integrase gene
(intP4-2) (Fig. 5 andTable 6). IntP4-1 and IntP4-2 share only 43%
amino acid identity, making it certain that they are not the result
of an internal duplication. A comparison of integrase sequences
associatedwith pheV islands indicated thatVR50 intP4-1 shares 94
to 95% nucleotide identity with the pheV-associated integrase
genes of SMS-3-5 and E24377A. VR50 intP4-2 shares at least 94%
nucleotide identity with the integrase genes of most other pheV
islands from E. coli genomes (e.g., Int PAI V536) and 98 to 99%
identity with int genes from Nissle 1917, CFT073, and UMN026
pheV islands.
The PAI-536-pheV (PAI V536) island has been extensively
FIG 4 Genetic locus map of the 94-kb GI-VR50-pheV island and adjacent kps capsular biosynthesis gene cluster from E. coli VR50 (drawn to scale). The arrows
showing genes are colored according to the modules shown in Fig. 5. IntP-like integrase genes, the pheV tRNA gene, and pheV repeats (phe=V and phe=V -2) are
colored black. Insertion sequences are shown as white arrows andmay containmore than one coding sequence (CDS). Direct repeats (172 nt) are shown as boxes
adjacent to phe=V and phe=V -2. Degenerate or truncated genes or insertion sequences are labeled with an apostrophe. GI-VR50-pheV is a composite genomic
island formed from two independent integrase-mediated insertions.
TABLE 5 Characteristics of pheV genomic islands from different E. coli strains
Genomic islanda Alternate name Size (nt)b Genome position (nt) Accession no.c
GI-VR50-pheV NAd 93,983 3295095–3389077 This study
GI-Nissle1917-pheV GEI-IINISSLE1917 77,685 NA (AJ586888)
GI-CFT073-pheV PAI-ICFT073 104,676 3406225–3510900 AE014075 (AF081285)
GI-UMN026-pheV NA 82,784 3445924–3528707 CU928163
GI-536-pheV PAI-V536 48,805 3128084–3176888 CP000247 (AJ617685)
GI-APECO1-pheV NA 55,888 3305017–3360904 CP000468 (DQ095216)
GI-SMS-3-5-pheV NA 91,940 3197159–3289098 CP000970
GI-S88-pheV NA 55,896 3219801–3275696 CU928161
GI-ED1a-pheV NA 135,753 3374807–3510560 CU928162
GI-55989-pheV NA 110,593 3339841–3450433 CU928145
GI-IAI39-pheV NA 38,534 3545466–3583999 CU928164
GI-E24377A-pheV NA 101,766 3325510–3427276 CP000800
a The APECO1 and S88 pheV islands are virtually identical (99% at the nucleotide level); the transposition of a 2,581-nt insertion sequence is the only substantial difference (data
not shown).
b The size was calculated from the first nucleotide of pheV to the last nucleotide of the phe=V direct repeat. No repeat was identified in GI-ED1a-pheV or GI-IAI39-pheV, and the
right-hand junction was taken as the breakpoint adjacent to the kpsF locus. E24377A contains a composite arrangement of two islands, similar to VR50 (data not shown).
c The GenBank accession number for the complete genome sequence, where available. Accession numbers in parentheses refer to GenBank accession numbers for genomic islands,
if published separately prior to the genome sequence. AF081285 covers only 13,710 bp of the CFT073 genomic island.
d NA, not applicable.
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studied and found to excise at lower frequencies than other E.
coli 536 pathogenicity islands, possibly due to a single-nucleotide
deletion in the right-handDR (54). Interestingly, the left-handDR
of pheV islands from VR50, Nissle 1917, CFT073, and UMN026
contain a single-nucleotide substitution thatmay also increase the
stability of the islands in these strains and suggests recent inheri-
tance from a common ancestor (Table 6). The close relationship
between these islands is borne out by the high nucleotide identity
of the sharedmodules. The composite structure of GI-VR50-pheV
suggests that there have been 2 independent insertions of unre-
lated pheV islands, although the actual polarity of this process is
unclear. The existence of composite pheV islands in E. coli high-
lights the capacity of these elements to generate variability.
GI-VR50-pheV contributes to colonization of themouse uri-
nary tract. To assess the contribution of GI-VR50-pheV to the
ability of E. coli VR50 to colonize the mouse urinary tract, we
deleted the islandusing-Red-mediated homologous recombina-
tion. This resulted in the replacement of the entire 94-kb island
with a kanamycin resistance gene cassette (referred to as
VR50pheV-GI). E. coli VR50 colonized the mouse bladder in high
numbers, demonstrating its suitability in this infection model.
However, we observed significantly reduced colonization of the
bladder by VR50pheV-GI compared to the wild-type VR50 strain
(P 0.002) (Fig. 6). Thus, GI-VR50-pheV contributes to the abil-
ity of E. coli VR50 to colonize the mouse bladder. Based on our
bioinformatic analysis of GI-VR50-pheV, we predicted that this
FIG 5 Comparison of the GI-VR50-pheV island with pheV genomic islands from other E. coli strains. The schematic diagram shows pheV genomic islands from
E. coli strains VR50, Nissle 1917, CFT073, UMN026, 536, APECO1, and SMS-3-5. Conservedmodules are colored the same and named for the best-known locus
or gene. Strain-specific modules are colored dark gray. Insertion sequences (often comprising more than one CDS) are represented as unfilled arrowheads. The
P4-like integrase sequences are represented as black arrowheads. The pheV and phe=V direct repeats denote the boundaries of each island. The kpsF and kpsM
modules, which are not considered part of the island, are colored light gray; variation in the gene content of the kpsM module is not shown. Inversions of
individual modules relative to the VR50 genome are shown with an asterisk adjacent to the module name. The diagram is drawn to scale.
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phenotype was directly associated with production of the Afa ad-
hesin and tested this hypothesis (see below).
Phylogenetic analysis of the AfaE adhesin. We performed a
phylogenetic analysis of the E. coli VR50 adhesin-encoding afaE
gene. The closest homologues of AfaE were the group 254 Dr
family adhesins, which were sequenced as part of a larger study
investigating the diversity of Dr family adhesin-encoding genes
from 100 E. coli isolates (55). The authors divided the Dr family
into 8 distinct groups (afaE-1, afaE-2, afaE-5, nfaE-111, daaE,
drbE, draE, and 254). A multiple-sequence alignment of VR50
afaE with the group 254 adhesin gene sequences showed only be-
tween five and nine nucleotide substitutions relative to other
group members (98% nucleotide sequence identity). Four of
these substitutions are unique to VR50 and are found in the 3=
region; two VR50 substitutions cause nonsynonymous replace-
ments of the terminal residues (GGYWAK to GGYWTN). Inter-
estingly, the same substitutions are found in another subgroup
(DaaE). Although no binding function has been described for
the C-terminal residues of the Dr adhesin, the observation that
positive selection of point mutations drives changes for adhe-
sin specificity in the DraE subfamily (55) leads us to speculate
that this region may be important for binding of VR50 in the
urinary tract. As yet, no information has been provided about
the origins of the isolates carrying group 254 adhesins; how-
ever, the closest functionally characterized homologue is
AfaE-3 (GenBank accession no. CAA54121).
TheAfa adhesin is functionally expressed on the surface ofE.
coliVR50. Phenotypic assays previously demonstrated that E. coli
VR50 causes weak MR hemagglutination of human type A RBCs
(20). This property is consistent with Afa adhesin surface expres-
sion. To confirm this, we constructed mutants with afaABCDE
deleted (VR50afa; Afa gene clustermutant) andwith the afaE gene
deleted (VR50afaE) using-Red-mediated homologous recombi-
nation. In contrast to E. coli VR50, the VR50afa and VR50afaE
mutants did not cause MR hemagglutination of human type A
RBCs (Fig. 7A), thus confirming the functional expression of Afa
by E. coli VR50.
Afa mediates adherence of E. coli VR50 to human bladder
epithelial cells. To examine the adhesion phenotype of E. coli
VR50 with respect to the urinary tract, we tested its ability to
adhere to T24 bladder epithelial cells. E. coli VR50 adhered
strongly to these cells (Fig. 7B). Next, we examined the adhesion
phenotype of the VR50pheV-GI, VR50afa, and VR50afaE mu-
tants. All threemutants displayed a significant reduction in adher-
ence to T24 bladder epithelial cells (P	 0.001) (Fig. 7B). Interest-
TABLE 6 Alignment of pheV and phe=V DR at genomic-island
boundaries
pheV island Direct-repeat sequencea Descriptor
VR50 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
VR50 phe=V TTTCATTCCGATTCCGGGCACCA 19/19-nt DR
VR50 phe=V2 TTTCATTCCGAGTCCGGGCACCA 19/19-nt DR
Nissle pheV TTCGATTCCGAGTCCGGGCACCA 54–76
Nissle phe=V TTTCATTCCGATTCCGGGCACCA 19/19-nt DR
CFT073 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
CFT073 phe=V TTTCATTCCGATTCCGGGCACCA 19/19-nt DR
UMN026 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
UMN026 phe=V TTTCATTCCGATTCCGGGCACCA 19/19-nt DR
536 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
536 phe=V TTCGATTCCGAGTCCGG-CACCA 23/22-nt DR
APECO1 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
APECO1 phe=V TTCGATTCCGAGTCCGG-CACCA 23/22-nt DR
SMS_3_5 pheV TTCGATTCCGAGTCCGGGCACCA 54–76
SMS_3_5 phe=V TTTTATTCCGAGTCCGGGCACCA 19/19-nt DR
a The columns in boldface contain differences (underlined) in phe=V (the direct repeat
at the 3= end of island) relative to the pheV tRNA gene. The nucleotides in italics are not
considered part of the phe=V repeat. The complete 76-nt pheV tRNA gene is 100%
identical in all the E. coli strains shown here.
FIG 6 Persistence of E. coli VR50, VR50pheV-GI, VR50afa, and VR50afaE in
the bladders of C57BL/6 mice 18 h after intraurethral challenge. The results
represent log10 CFU/0.1 g bladder tissue of individualmice, and the horizontal
bars mark group medians. A minimum of 8 mice were assessed per group. E.
coli VR50 was recovered from the bladders of infected mice in significantly
higher numbers than each of the mutant strains (P  0.002; Kruskal-Wallis
test).
FIG 7 (A) VR50 expresses functional Afa. Shown is hemagglutination of hu-
man RBCs by E. coli VR50 (i) in contrast to E. coli VR50afa (ii), which was
unable to mediate hemagglutination of human RBCs under the same condi-
tions. The images were viewed under 63 magnification. (B) Adhesion of E.
coli VR50, VR50pheV-GI, VR50afa, VR50afaE, VR50fim, and VR50fimH to
T24 human bladder epithelial cells. The epithelial cells were inoculated with
bacteria and incubated for 1 h, with adherent bacteria enumerated by direct
plating and colony counts. The results are the averages of two independent
experiments plus standard errors of the mean. Mutant strains VR50pheV-GI,
VR50afa, and VR50afaE adhered significantly less to T24 cells than wild-type
VR50 and the two type 1 fimbria-deficient mutants, VR50fim and VR50fimH
(P	 0.001; analysis of variance [ANOVA]).
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ingly, mutants of VR50 with the entire type 1 fimbrial gene cluster
(VR50fim) or the fimH gene (VR50fimH) deleted did not show
any significant difference in adherence to T24 bladder epithelial
cells compared to the parent VR50 strain. Taken together, the data
support a role for the AfaE adhesin of E. coli VR50 in adhesion to
human bladder epithelial cells.
Afa contributes to colonization of the mouse bladder by E.
coli VR50. In light of the above in vitro adherence data and the in
vivomouse colonization phenotype of VR50pheV-GI, we tested E.
coli VR50afa and VR50afaE for the ability to colonize and survive
in the mouse urinary tract following transurethral infection (Fig.
6). E. coli VR50afa and VR50afaE were both significantly attenu-
ated for colonization of the mouse bladder. The degree of attenu-
ationwas identical to that observed forE. coliVR50pheV-GI, dem-
onstrating a direct role for the Afa adhesin in colonization. No
significant colonization of the kidneys was observed for VR50 or
any of the mutants; this is consistent with previous data from our
laboratory using C57BL/6 mice (56, 57).
DISCUSSION
ABU E. coli strains, which colonize the human urinary tract with-
out causing symptoms, comprise strains that have become atten-
uated through gene loss or deletion (e.g., E. coli 83972), as well as
commensal-like strains that have acquired fitness factors that fa-
cilitate colonization of the human bladder. Here, we demonstrate
that E. coli VR50 is an example of a commensal E. coli strain that
has gained important genes to enable it to survive in the urinary
bladder.
The complete genome sequence of VR50 revealed multiple ac-
cessory genes that may contribute to its survival in the human
urinary tract. In general, these genes were associated with a range
of mobile genetic elements, including plasmids, prophages, and
genomic islands. We identified 8 prophage regions in the VR50
chromosome, 4 of which are likely to be functional, with another
2 encoding satellite phage. Several putative cargo gene products
are encoded within the prophage regions, most of which have
unknown functions, but some have similarity to known proteins,
e.g., DinI-like damage-inducible proteins (VR50p6), outer-mem-
brane porin proteins (VR50p2 and VR50p6), Lom-like outer-
membrane proteins (VR50p2, VR50p4, and VR50p6), and a DNA
adenine methylase (VR50p7). E. coli VR50 also carries two large
plasmids, one of which contains several antibiotic resistance
genes. Prophages, genomic islands, and plasmids are themselves
comprised of smaller mobile genetic elements, some of which ap-
pear to have undergone expansion in VR50 since its divergence
from other group A E. coli strains. For example, the IS629 element
is not found in E. coli K-12 MG1655, but there are 19 copies dis-
tributed throughout the E. coliVR50 chromosome, including dis-
ruptive insertions within genes encoding putative outer-mem-
brane proteins and chaperone-usher fimbriae (see Data Set S1 in
the supplemental material).
We focused a major part of our analysis on the GI-VR50-pheV
island, which contains multiple virulence-associated genes, in-
cluding those encoding Afa, Ag43, Sat, and aerobactin. Lloyd et al.
recommended that GIs are differentiated from PAIs by the fact
that the latter contain established or putative virulence genes
whereas the former contain genes with unknown functions (58).
The original criteria for classifying pathogenicity islands suggested
that the term should be reserved for islands preferentially associ-
ated with pathogenic strains (59). It is clear from a simple com-
parison of pheV-associated islands in commensal, pathogenic, and
asymptomatic strains that there are no apparent qualitative differ-
ences between GIs and PAIs, so use of the more neutral GI termi-
nology may be more appropriate to describe integrated islands in
the VR50 genome. Direct repeats can often be used to distinguish
between integrative islands that appear to play such a dynamic
role in the adaptation to new environments (e.g., PAI-536-pheV
and PAI-CFT073-pheV) and lineage-specific indels. Delineating
these boundaries is not always trivial, as the GI-pheV case demon-
strates. For example, the kps capsule biosynthesis locus is included
within the island boundaries in the original report of the Nissle
1917 pheV island (48). Similarly, a comparison of several pheV
islands does not distinguish between the integrative island at the
pheV gene and downstream variability in the kps and gsp loci, even
though much of the gsp secretion locus is present in a syntenic
location in the Escherichia fergusonii genome (49). Recent studies
of the E. coli ST131 lineage by our group have begun to reveal the
extent of recombination associated with GI-pheV and other mo-
bile genetic elements (60).
The GI-VR50-pheV island is very similar to pheV-associated
islands from awide variety of sequenced strains, e.g., the probiotic
E. coli Nissle 1917, extraintestinal pathogenic E. coli (ExPEC)/
UPEC (CFT073,UMN026, IA39, S88, 536, andAPECO1), entero-
toxigenic E. coli (ETEC) (E24377A), enteroaggregative E. coli
(EAEC) (55989), and commensal (ED1a) and environmental
(SMS-3-5) strains. Remarkably, the LEE has been associated with
pheV islands in rabbit enteropathogenic (EPEC) (51) and STEC
(61). It appears that these integrative islands aremodular, and this
mosaicism could be the key factor in their success, allowing rapid
insertion and deletion of new elements that provide a selective
advantage in different environments. In the case of E. coli VR50,
our molecular analyses suggest that a selective advantage is pro-
vided by the acquisition of the Afa/Dr adhesin locus. Another
interesting consequence of this modularity is that there is exten-
sive exchange between islands via homologous recombination.
For example, although E. coli UTI89 lacks the pheV island, many
of the core modules found on GI-VR50-pheV (e.g., sat, iut, and
flu) are found on other UTI89 islands. As the number of complete
genomes increases, it should be possible to obtain a clearer picture
of the role that integrative islands play in pathogen evolution.
It is an open question as to what role the other pheV island-
encoded “pathogenicity factors,” such as the sat gene product and
aerobactin, play in the life styles of VR50 and other intestinal
commensal organisms. Given the ease with which elements or the
entire island are lost from these loci in some strains (54), it appears
that these elements are under strong selective pressure to be re-
tained. In the case of VR50, the presence of a complete aerobactin
gene locus and the gene encoding the Iha siderophore receptor
within GI-VR50-pheV suggests these genesmight contribute to its
overall fitness in the bladder. Iron is a limiting nutrient in the
human urinary tract, and UTI E. coli strains often produce several
siderophores to acquire ferric iron (Fe3
) from the host. Four
siderophore systems have been described from UTI E. coli, i.e.,
enterobactin (which is common to all strains), salmochelin, yers-
iniabactin, and aerobactin (62, 63). Indeed, UPEC mutants with
genes encoding the production of siderophores deleted are less
virulent in the mouse urinary tract (64). An enhanced ability of
ABU E. coli strains to acquire iron has also been proposed as a
mechanism by which they outcompete UPEC during growth in
human urine (39, 63, 65). We did not observe any significant
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difference in the overall level of siderophores produced by E. coli
strains MG1655 and VR50 as measured by the chrome azurol S
(CAS) assay (reference 66 and data not shown); however, this is
most likely due to the common production of enterobactin by
both strains.
GI-VR50-pheVwas shown to contribute to the ability of E. coli
VR50 to colonize the mouse urinary tract, and we further defined
Afa as a GI-encoded factor that mediates adherence of VR50 to
T24 bladder epithelial cells. The Afa (andDr) adhesins comprise a
family of surface-located factors encoded by the afa (67–71), dra
(72, 73), and daa (74, 75) operons. These operons possess similar
genetic structures and have been associated with E. coli strains of
diarrheagenic and UTI origin (76, 77). Many Afa adhesins recog-
nize as a receptor the decay-accelerating factor (DAF), a comple-
ment-regulatory protein present on the surfaces of a range of hu-
man epithelial cells (including epithelial cells of the urinary tract)
(78, 79). Some Afa variants also mediate binding to type IV colla-
gen and carcinoembryonic antigen-related cell adhesion mole-
cules (80, 81). We demonstrated a role for Afa (but not type 1
fimbriae) in the adhesion of E. coliVR50 to T24 bladder epithelial
cells. Afa has been shown tomediate adherence and invasion of E.
coli inHeLa andChinese hamster ovary cells (82, 83). In the case of
VR50, we previously reported that the strain does not readily in-
vade T24 cells, with low numbers observed intracellularly (84).
However, it is possible that the E. coli VR50 cells recovered from
HeLa cells in our assay may represent both adhered and intracel-
lular bacteria. In themouseUTImodel, E. coliVR50 colonized the
bladder with high efficiency, and the overall cell numbers were
very similar to the level of colonization we routinely observe for
CFT073 (56, 57, 85). In contrast, VR50pheV-GI, VR50afa, and
VR50afaE all displayed significantly attenuated colonization of
the mouse bladder, strongly suggesting that the afa genes within
GI-VR50-pheV enhance the fitness of VR50 in the urinary tract.
The innate immune response is essential for defense against
UTI, and the associated tissue inflammation is a major cause of
symptoms, leading to tissue damage and contributing to the se-
verity of disease. The innate response is affected by the virulence of
the infecting strain, andmanywell-characterized virulence factors
act by triggering inflammation. UPEC triggers the secretion of
epithelial cytokines and chemokines that contribute to inflamma-
tion and pathology. For example, IL-6 levels in the urine correlate
with disease severity, and IL-8 results in recruitment of neutro-
phils to the site of infection (86–88). Despite equivalent adherence
to epithelial cells, E. coli CFT073 triggered a significantly stronger
IL-6 cytokine response than E. coli VR50. This property may be
associatedwith the ability ofE. coliVR50 to colonize the bladder in
high numbers without provoking a host inflammatory response
and is consistent with the low IL-6 response observed in individ-
uals deliberately colonized with E. coli 83972 (89). It remains to be
determined if VR50 is able to suppress RNApolymerase II-depen-
dent host gene expression, as has been reported recently for E. coli
83972 (19). Furthermore, host genetic variation that leads to sup-
pression of the innate immune response to UTI (e.g., via Toll-like
receptor 4 [TLR4] promoter polymorphisms) also contributes to
protection against symptomatic disease in some ABU patients
(90–93).
ABU occurs in up to 6% of healthy individuals, 18% of diabet-
ics (mostly women), and 20%of elderly individuals (womenmore
often thanmen). E. coli is also themost frequent cause of ABU. An
understanding of the molecular mechanisms that underpin ABU
would have a major impact on current approaches to treating and
preventing symptomatic UTI for several reasons. First, ABU
strains provide a unique model to identify factors that enable
UPEC to colonize the urinary tract. Second, the outcomes of ABU
vary; in some patients, ABU can predispose to kidney infection,
while in other patients, ABU can prevent colonization by more
virulent strains. A greater understanding of the risk factors asso-
ciated with ABU is therefore required to guide treatment deci-
sions. Third, the unnecessary treatment of ABU in some patients
may be associated with the rapid spread of genes coding for anti-
biotic resistance, particularly in health care settings. In this re-
spect, it is interesting that E. coli VR50 contains a truncated copy
of the blaTEM-1 gene. Although not functional, a significant asso-
ciation between ampicillin resistance and the presence of the afa
and dra genes has been reported previously (94). Finally, ABU E.
coli represents a viable prophylactic approach for the prevention
and treatment of chronic and recurrent UTIs. The use of ABU E.
coli as a prophylactic agent could address important concerns
about antibiotic resistance in patients with UTI recalcitrant to
treatment with currently available antibiotics. In the case of VR50,
its capacity to express Afa, which contributes to chronic pyelone-
phritis (77, 95) and recurrent cystitis (96), suggests that it would
not constitute a suitable prophylactic ABU strain for human use.
In summary, our study has determined the complete genome
sequence of E. coliVR50 and demonstrated that it is a commensal-
like strain that has acquired a number of UPEC-associated viru-
lence factors. One of these factors, Afa, contributes specifically to
VR50 colonization of the mouse bladder.
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